Dana-Farber News
@danafarbernews.bsky.social
Heading to #SABCS25? Check out new research being shared by @danafarber.bsky.social faculty members on QoL for young breast cancer survivors, targeted agents in MBC, use of ctDNA to predict expectational responders, and more:
➡️ bit.ly/44SUSoy
➡️ bit.ly/44SUSoy
December 5, 2025 at 6:30 PM
Heading to #SABCS25? Check out new research being shared by @danafarber.bsky.social faculty members on QoL for young breast cancer survivors, targeted agents in MBC, use of ctDNA to predict expectational responders, and more:
➡️ bit.ly/44SUSoy
➡️ bit.ly/44SUSoy
New research in @jacs.acspublications.org by @danafarber.bsky.social’s Jun Qi, PhD, and Movassaghi Lab @mitchemistry.bsky.social shows the interaction between (+)-verticillin A and its derivatives with EZHIP may be leveraged to treat pediatric cancers sensitive to H3K27me3 alteration. bit.ly/3XBc0eC
December 3, 2025 at 8:00 PM
New research in @jacs.acspublications.org by @danafarber.bsky.social’s Jun Qi, PhD, and Movassaghi Lab @mitchemistry.bsky.social shows the interaction between (+)-verticillin A and its derivatives with EZHIP may be leveraged to treat pediatric cancers sensitive to H3K27me3 alteration. bit.ly/3XBc0eC
At #ASH25 in Orlando from December 6-9, @danafarber.bsky.social will present more than 120 studies from lab to clinical trials to advance patient care. Highlighted research features: chemo-free B-cell lymphoma, sickle cell insights, HR-MDS, and pediatric ALL.
Read more: bit.ly/4aseuU5
Read more: bit.ly/4aseuU5
December 2, 2025 at 7:30 PM
At #ASH25 in Orlando from December 6-9, @danafarber.bsky.social will present more than 120 studies from lab to clinical trials to advance patient care. Highlighted research features: chemo-free B-cell lymphoma, sickle cell insights, HR-MDS, and pediatric ALL.
Read more: bit.ly/4aseuU5
Read more: bit.ly/4aseuU5
Researchers from @danafarber.bsky.social are presenting 120+ studies at #ASH25. From non-chemo, time-limited lymphoma approaches (including Waldenström’s) to early sickle cell insights, Phase 3 MDS subgroup data, pediatric ALL, BPDCN, GVHD, and PROMISE screening.
Highlights: bit.ly/3XgqNLI
Highlights: bit.ly/3XgqNLI
November 25, 2025 at 3:00 PM
Researchers from @danafarber.bsky.social are presenting 120+ studies at #ASH25. From non-chemo, time-limited lymphoma approaches (including Waldenström’s) to early sickle cell insights, Phase 3 MDS subgroup data, pediatric ALL, BPDCN, GVHD, and PROMISE screening.
Highlights: bit.ly/3XgqNLI
Highlights: bit.ly/3XgqNLI
Brandon Huffman, MD, and @danafarber.bsky.social patient Debby spoke with @nbcboston.com's Monica Madeja about a potentially game-changing clinical trial offering a pill to treat #PancreaticCancer. November is #PancreaticCancerAwareness month.
➡️ bit.ly/4ogwnIV
➡️ bit.ly/4ogwnIV
New drug offers hope for pancreatic cancer patients
A new oral drug in its final trial phase could be a gamechanger in the fight against pancreatic cancer, and a Worcester woman who was part of the trial shared how it helped shrink her tumor.
bit.ly
November 22, 2025 at 2:00 PM
Brandon Huffman, MD, and @danafarber.bsky.social patient Debby spoke with @nbcboston.com's Monica Madeja about a potentially game-changing clinical trial offering a pill to treat #PancreaticCancer. November is #PancreaticCancerAwareness month.
➡️ bit.ly/4ogwnIV
➡️ bit.ly/4ogwnIV
Heading to #CTOS25? Check out this list of @danafarber.bsky.social research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.
November 11, 2025 at 3:30 PM
Heading to #CTOS25? Check out this list of @danafarber.bsky.social research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.
In commentary published in Cancer Cell, @danafarber.bsky.social’s @judithagudo.bsky.social contends that integrating cancer cell phenotypic heterogeneity into spatial analyses is essential to reveal the mechanisms that generate TIME diversity and address resistance to immunotherapy. bit.ly/496Mc0Y.
November 7, 2025 at 3:30 PM
In commentary published in Cancer Cell, @danafarber.bsky.social’s @judithagudo.bsky.social contends that integrating cancer cell phenotypic heterogeneity into spatial analyses is essential to reveal the mechanisms that generate TIME diversity and address resistance to immunotherapy. bit.ly/496Mc0Y.
Now in Immunity: Research led by @vanallenlab.bsky.social finds immunotherapy resistance in #KidneyCancer is driven by myeloid cell signaling. This could help identify biomarkers to predict which patients are likely to respond to immunotherapy. @danafarber.bsky.social
➡️ bit.ly/47A0eWk
➡️ bit.ly/47A0eWk
October 31, 2025 at 3:40 PM
Now in Immunity: Research led by @vanallenlab.bsky.social finds immunotherapy resistance in #KidneyCancer is driven by myeloid cell signaling. This could help identify biomarkers to predict which patients are likely to respond to immunotherapy. @danafarber.bsky.social
➡️ bit.ly/47A0eWk
➡️ bit.ly/47A0eWk
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
October 29, 2025 at 11:15 PM
Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.
➡️ bit.ly/3JxnaO5
➡️ bit.ly/3JxnaO5
Melissa Levin, MSW, LICSW, tells @gohealio.bsky.social that @danafarber.bsky.social utilizes an ADA coordinator, director of interpreter services, neuro-inclusive social worker and disability competency care committee to make healthcare accessible and inclusive for patients with IDD. bit.ly/3JthuED
Q&A: Better support can improve inpatient psychiatric care for patients with IDD
Patients with intellectual and developmental disabilities make up a disproportionate share of individuals occupying long-stay psychiatric inpatient hospital beds in Ontario, according to data from the Azrieli Adult Neurodevelopmental Centre. Published in The Canadian Journal of Psychiatry, the study also found that only 5.3% of these patients were in units specialized for intellectual and
bit.ly
October 29, 2025 at 3:30 PM
Melissa Levin, MSW, LICSW, tells @gohealio.bsky.social that @danafarber.bsky.social utilizes an ADA coordinator, director of interpreter services, neuro-inclusive social worker and disability competency care committee to make healthcare accessible and inclusive for patients with IDD. bit.ly/3JthuED
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
October 28, 2025 at 2:48 PM
Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
➡️ bit.ly/4qvbFao
📷 Stephanie Berenson Photography
In a study published in the Journal of Pediatric Psychology, @danafarber.bsky.social’s Dr. Eric Zhou highlights the Dana-Farber/Boston Children's Cancer and Blood Disorders Center’s new Sleep ALL Night program aiming to help children with leukemia sleep better during treatment. #ALL bit.ly/3Jxns7w
October 27, 2025 at 6:00 PM
In a study published in the Journal of Pediatric Psychology, @danafarber.bsky.social’s Dr. Eric Zhou highlights the Dana-Farber/Boston Children's Cancer and Blood Disorders Center’s new Sleep ALL Night program aiming to help children with leukemia sleep better during treatment. #ALL bit.ly/3Jxns7w
Reposted by Dana-Farber News
Thank you to the Blavatnik Family Foundation and The New York Academy of Sciences for honoring our research uniting human innate immunity and bacterial anti-phage defense at @danafarber.bsky.social @harvardmicro.bsky.social @harvard.edu
bit.ly/4pZUDkF
blavatnikawards.org/news/items/t...
bit.ly/4pZUDkF
blavatnikawards.org/news/items/t...
October 9, 2025 at 4:44 PM
Thank you to the Blavatnik Family Foundation and The New York Academy of Sciences for honoring our research uniting human innate immunity and bacterial anti-phage defense at @danafarber.bsky.social @harvardmicro.bsky.social @harvard.edu
bit.ly/4pZUDkF
blavatnikawards.org/news/items/t...
bit.ly/4pZUDkF
blavatnikawards.org/news/items/t...
Congratulations to @danafarber.bsky.social’s Tomer Yaron-Barir, MD, PhD, who has been selected by @statnews.com as one of this year's #STATWunderkinds recognizing unheralded heroes of science and medicine.
Read more: bit.ly/3Js8S15
Read more: bit.ly/3Js8S15
October 24, 2025 at 5:30 PM
Congratulations to @danafarber.bsky.social’s Tomer Yaron-Barir, MD, PhD, who has been selected by @statnews.com as one of this year's #STATWunderkinds recognizing unheralded heroes of science and medicine.
Read more: bit.ly/3Js8S15
Read more: bit.ly/3Js8S15
Congratulations to Milen Negasi, a researcher in Dr. Xin Gu’s lab at @danafarber.bsky.social, who has been named to the Damon Runyon Scholars Program for Advancing Research and Knowledge (SPARK). The one-year cancer research internship is awarded to post-baccalaureate scholars.
October 23, 2025 at 6:30 PM
Congratulations to Milen Negasi, a researcher in Dr. Xin Gu’s lab at @danafarber.bsky.social, who has been named to the Damon Runyon Scholars Program for Advancing Research and Knowledge (SPARK). The one-year cancer research internship is awarded to post-baccalaureate scholars.
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv
October 21, 2025 at 7:35 PM
New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer.
bit.ly/3Jq2Yxv
bit.ly/3Jq2Yxv
Promising results for new combination therapy for ER+ HER2- #BreastCancer - Data presented by @danafarber.bsky.social’s Erica Mayer, MD, MPH, at #ESMO25 shows the combo may address resistance that often develops with current endocrine therapies. ➡️ bit.ly/46VQwyz
October 18, 2025 at 8:30 AM
Promising results for new combination therapy for ER+ HER2- #BreastCancer - Data presented by @danafarber.bsky.social’s Erica Mayer, MD, MPH, at #ESMO25 shows the combo may address resistance that often develops with current endocrine therapies. ➡️ bit.ly/46VQwyz
Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study.
Press release ➡️bit.ly/47oV0hd
Press release ➡️bit.ly/47oV0hd
October 17, 2025 at 2:05 PM
Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study.
Press release ➡️bit.ly/47oV0hd
Press release ➡️bit.ly/47oV0hd
As we observe Patient-Centered Care Awareness Month throughout October, we acknowledge our Nursing and Patient Care Services team whose clinical expertise, support and compassion shape every patient’s experience and set @danafarber.bsky.social apart.
Learn more about our approach at bit.ly/3Hec4wm.
Learn more about our approach at bit.ly/3Hec4wm.
October 16, 2025 at 2:00 PM
As we observe Patient-Centered Care Awareness Month throughout October, we acknowledge our Nursing and Patient Care Services team whose clinical expertise, support and compassion shape every patient’s experience and set @danafarber.bsky.social apart.
Learn more about our approach at bit.ly/3Hec4wm.
Learn more about our approach at bit.ly/3Hec4wm.
Breast, prostate, lung, and bladder cancers, as well as important studies on antibody-drug conjugates, are some of the most anticipated studies at #ESMO25. Scientific co-chair Toni Choueiri, MD, of @danafarber.bsky.social shared key takeaways with @oncologynews.bsky.social.
➡️ bit.ly/47nbkPw
➡️ bit.ly/47nbkPw
Practice-Changing Data Expected at ESMO 2025: What to Watch for
Practice-changing data in prostate, breast, and lung cancers are set for the 2025 ESMO Annual Congress on Oct. 17–21. Here is some of what experts are anticipating.
bit.ly
October 15, 2025 at 3:00 PM
Breast, prostate, lung, and bladder cancers, as well as important studies on antibody-drug conjugates, are some of the most anticipated studies at #ESMO25. Scientific co-chair Toni Choueiri, MD, of @danafarber.bsky.social shared key takeaways with @oncologynews.bsky.social.
➡️ bit.ly/47nbkPw
➡️ bit.ly/47nbkPw
Reposted by Dana-Farber News
Join us in congratulating Jessica A. Pollard, MD, on receiving the 2025 Healing Hero of Excellence in Pediatric Oncology award from Kids Beating Cancer, recognizing her compassionate care and dedication to advancing childhood cancer cures.
October 11, 2025 at 12:30 PM
Join us in congratulating Jessica A. Pollard, MD, on receiving the 2025 Healing Hero of Excellence in Pediatric Oncology award from Kids Beating Cancer, recognizing her compassionate care and dedication to advancing childhood cancer cures.
Important studies in breast, lung, and bladder cancers led or co-led by @danafarber.bsky.social researchers will be presented at #ESMO25 this week in Berlin. The ESMO Congress is one of the most important global oncology meetings and runs Oct 17-21.
Press release ➡️ bit.ly/4q1uodx
Press release ➡️ bit.ly/4q1uodx
October 14, 2025 at 12:00 PM
Important studies in breast, lung, and bladder cancers led or co-led by @danafarber.bsky.social researchers will be presented at #ESMO25 this week in Berlin. The ESMO Congress is one of the most important global oncology meetings and runs Oct 17-21.
Press release ➡️ bit.ly/4q1uodx
Press release ➡️ bit.ly/4q1uodx
What’s known about early-onset cancer and what someone can do to mitigate their risk? Learn more in this in-depth conversation and podcast with The Harvard Gazette, featuring @danafarber.bsky.social’s @timrebbeck.bsky.social and Dr. Kimmie Ng.
➡️ bit.ly/46HoHdg
➡️ bit.ly/46HoHdg
Cancer is rising among younger people - why? - Harvard Gazette
In podcast, experts outline potential factors driving trend and how to reduce risk.
bit.ly
October 10, 2025 at 3:00 PM
What’s known about early-onset cancer and what someone can do to mitigate their risk? Learn more in this in-depth conversation and podcast with The Harvard Gazette, featuring @danafarber.bsky.social’s @timrebbeck.bsky.social and Dr. Kimmie Ng.
➡️ bit.ly/46HoHdg
➡️ bit.ly/46HoHdg
Sara Tolaney, MD, of @danafarber.bsky.social joined @boston25news.com to discuss the latest in breast cancer treatment, trends and screening.
➡️ bit.ly/3WvxUze
➡️ bit.ly/3WvxUze
Breast Cancer Awareness Month
Boston 25 Weather The Local Life(Opens in new window) Share your pics(Opens in new window)
bit.ly
October 9, 2025 at 2:32 PM
Sara Tolaney, MD, of @danafarber.bsky.social joined @boston25news.com to discuss the latest in breast cancer treatment, trends and screening.
➡️ bit.ly/3WvxUze
➡️ bit.ly/3WvxUze
Patients should ask about testing colorectal cancer tumors for certain mutation as aspirin may help prevent recurrence, explains @danafarber.bsky.social’s Dr. Jeff Meyerhardt in @everydayhealth.bsky.social.
Read more here: bit.ly/4nsQh3I
Read more here: bit.ly/4nsQh3I
Aspirin Can Reduce the Risk of Colon Cancer Returning for Some People
Taking daily low-dose aspirin could almost halve the risk of colorectal cancer recurrence for some patients whose tumors have a particular genetic mutation, a new study finds.
bit.ly
October 1, 2025 at 2:30 PM
Patients should ask about testing colorectal cancer tumors for certain mutation as aspirin may help prevent recurrence, explains @danafarber.bsky.social’s Dr. Jeff Meyerhardt in @everydayhealth.bsky.social.
Read more here: bit.ly/4nsQh3I
Read more here: bit.ly/4nsQh3I